摘要
目的分析p67蛋白在胰腺癌和癌旁组织中的表达及预后意义。方法共纳入90例胰腺导管腺癌患者,每位患者具有对应的癌组织和癌旁组织标本,采用免疫组织化学技术进行芯片染色,检测组织芯片中p67的表达,分析p67的表达与胰腺癌临床病理特征的关系,并进行生存分析及Cox回归分析探讨p67的预后价值。结果 90例胰腺癌组织中p67阳性表达率为57.8%。p67阳性表达与肿瘤大小及临床分期显著相关(均P<0.05)。p67在癌旁组织的阳性表达率与淋巴结转移、临床分期具有显著相关性(均P<0.05)。胰腺癌组织p67阳性组患者的总生存期(OS)短于p67阴性组患者(P<0.05),在癌旁组织中有相同趋势。Cox多因素分析显示癌旁组织p67阳性为胰腺癌不良预后的独立因素。结论 p67阳性表达预示胰腺癌的不良预后。p67抑制剂可能会改善胰腺癌患者的预后。
Objective To investigate the p67 expression in specimens of pancreas cancer and corresponding paracancerous tissues and its prognostic value.Methods The p67 expression in pancreas adenocarcinoma patients was detected by immunohistochemistry.The relationship between the p67 expression and clinicopathological features of pancreas cancer was analyzed.Survival analysis and the COX regression hazards model were used to study the prognostic value of p67 expression in pancreas cancer.Results The p67 positive expression rate in 90 pancreas cancer patients was 57.8%.The p67 expression was significantly associated with tumor size and clinical stage（P〈0.05）.The overall survival（OS）in patients positive for the p67 expression was shorter than in those negative for the p67expression（P〈0.05）.Multivariate analysis demonstrated that the p67 expression was independent predictor of poor prognosis in patients with pancreas cancer.Conclusion The p67 expression predicts a poor prognosis in patients with pancreas cancer.Overexpression of p67 shows a high probability of lymphatic metastasis in pancreas cancer.The p67 inhibition therapy may be necessary to improve the poor prognosis in patients with pancreas cancer.
出处
《华中科技大学学报（医学版）》
CAS
CSCD
北大核心
2016年第4期450-453,共4页
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
关键词
胰腺癌
p67
预后
组织芯片
pancreas cancer
p67
prognosis
tissue microarray
